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A B S T R A C T 
Objective: To validate a locally developed 
chromatography-based method to monitor 
emerging drugs of abuse whilst performing regular 
drug testing in abusers.
Design: Cross-sectional study.
Setting: Eleven regional hospitals, seven social 
service units, and a tertiary level clinical toxicology 
laboratory in Hong Kong. 
Participants: A total of 972 drug abusers and 
high-risk individuals were recruited from acute, 
rehabilitation, and high-risk settings between 1 
November 2011 and 31 July 2013. A subset of the 
participants was of South Asian ethnicity. In total, 
2000 urine or hair specimens were collected. 
Main outcome measures: Proof of concept that 
surveillance of emerging drugs of abuse can be 
performed whilst conducting routine drug of abuse 
testing in patients.
Results: The method was successfully applied 
to 2000 samples with three emerging drugs 
of abuse detected in five samples: PMMA 
(paramethoxymethamphetamine), TFMPP 
[1-(3-trifluoromethylphenyl)piperazine], and 
methcathinone. The method also detected 
conventional drugs of abuse, with codeine, 
methadone, heroin, methamphetamine, and 
ketamine being the most frequently detected drugs. 
Other findings included the observation that South 
Surveillance of emerging drugs of abuse in Hong 
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Introduction
Despite continuous efforts, drug abuse remains a 
major social and medical problem in today’s society. 
In particular, there has been a rapid and continued 
growth of ‘emerging’ drugs of abuse (DOA) on a global 
scale.1,2 Emerging DOA, also called designer drugs or 
New knowledge added by this study
• A locally developed method is a valid tool for monitoring the penetrance of emerging drugs of abuse into our 
society whilst performing regular drugs of abuse testing.
Implications for clinical practice or policy
• Implementation of the analytical method in the routine drug monitoring of drug abusers will enable 
simultaneous surveillance of novel drugs of abuse at minimal extra cost and effort.
• Continued and proactive surveillance of emerging drugs of abuse in the population will facilitate prompt 
measures in the clinical, social, and legislative management of these constantly changing and potentially 
dangerous drugs.
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novel psychoactive substances, bear a chemical and/
or pharmacological resemblance to conventional 
DOA and pose a threat to public health, but are 
often (initially) not controlled by law. They are easily 
accessible from street dealers or through the internet, 
and are often presumed to be safer than conventional 
ORIGINAL ARTICLE
Asians had significantly higher rates of using opiates 
such as heroin, methadone, and codeine; and that 
ketamine and cocaine had significantly higher 
detection rates in acute subjects compared with the 
rehabilitation population.
Conclusions: This locally developed analytical 
method is a valid tool for simultaneous surveillance 
of emerging drugs of abuse and routine drug 
monitoring of patients at minimal additional cost 
and effort. Continued, proactive surveillance and 
early identification of emerging drugs will facilitate 
prompt clinical, social, and legislative management.
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DOA owing to their ‘legal’ or ‘herbal’ nature.1,3 In 
Hong Kong, the drug scene has also been penetrated 
in recent years by such substances as the piperazine 
derivative TFMPP [1-(3-trifluoromethylphenyl)
piperazine],4 the synthetic cannabinoids,5 the 
methamphetamine derivative PMMA (para-
methoxymethamphetamine),6 and the NBOMe (N-
methoxybenzyl derivatives of phenethylamine).7 
Some of these novel drugs pose a significant health 
threat and numerous fatalities have been reported 
worldwide.8-10 In particular, PMMA and the NBOMe 
drugs have been associated with severe clinical 
toxicity and fatalities in Hong Kong.6,7
 Effective diagnosis and treatment of emerging 
DOA intoxication rely on the timely and accurate 
detection of these substances. Whilst immunoassay 
and drug screening methods are well-established 
for conventional DOA, laboratory analysis of novel 
drugs is not so readily available. This inevitably leads 
to the delayed discovery of emerging drugs and 
consequently early medical and social intervention 
is compromised. Recently, a liquid chromatography–
tandem mass spectrometry (LC-MS/MS)–based 
method has been established locally that allows the 
simultaneous detection of 47 commonly abused 
drugs in addition to over 45 emerging DOA and their 
metabolites in urine11 and hair (the latter manuscript 
in preparation). The aim of the current study was to 
validate this analytical method as a tool to monitor 
emerging DOA whilst performing regular DOA 
testing by applying the method to 2000 urine and 




Between 1 November 2011 and 31 July 2013, 964 
urine and 1036 hair specimens (n=2000 in total) were 
collected for analysis. Subjects who were included in 
the study were patients/clients of the units listed, and 
who were suspected to be actively using DOA and 
who agreed to participate in the study: (i) substance 
abuse clinics within the Hospital Authority (Castle 
Peak Hospital, Kowloon Hospital, Kwai Chung 
Hospital, Pamela Youde Nethersole Eastern Hospital, 
Prince of Wales Hospital, Queen Mary Hospital); (ii) 
accident and emergency (A&E) departments within 
the Hospital Authority (Pamela Youde Nethersole 
Eastern Hospital, Pok Oi Hospital, Princess Margaret 
Hospital, Queen Mary Hospital, Tuen Mun Hospital, 
United Christian Hospital, Yan Chai Hospital); (iii) 
the Hong Kong Poison Information Centre (HKPIC) 
toxicology clinic; (iv) counselling centres for 
psychotropic substance abusers (CCPSA; Evergreen 
Lutheran Centre, Rainbow Lutheran Centre, Cheer 
Lutheran Centre); (v) various rehabilitation centres 
including the Society of Rehabilitation and Crime 
Prevention (SRACP), Operation Dawn and Caritas 
Wong Yiu Nam Centre; and (vi) Youth Outreach. 
Pregnant women and individuals aged under 18 years 
were excluded from the study. The majority of the 
participants were Chinese, although those recruited 
from SRACP were exclusively South Asians.
 The study was approved by the institutional 
ethics review boards (Kowloon West Cluster: KW/
FR-11-011 (41-05); Kowloon Central/Kowloon East 
Cluster: KC/KE-11-0170/ER-2; Hong Kong West 
Cluster: UW 11-398; Hong Kong East Cluster: HKEC-
2011-068; New Territories West Cluster: NTWC/
CREC/989/11; New Territories East Cluster: CRE-
2011.427). Subjects donated samples on a voluntary 
basis and informed consent was obtained. Each 
subject donated either urine or hair, or both, at each 
donation episode. Some gave repeated sample(s): 
donations were at least 8 weeks apart. Urine was 
collected in a plain plastic bottle and frozen until 
analysis. For hair, a lock of hair was collected from 
the back of the head for analysis. The root end was 
identified to facilitate segmental analysis. 
Sample analysis
The methodology for urine analysis has been detailed 
in a separate publication.11 In brief, the urine sample 
was subjected to an initial glucuronidase digestion, 
followed by solid phase extraction and sample 
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TABLE 1.  The conventional and emerging drugs of abuse being 
analysed for
TABLE 1.  (cont'd)
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Abbreviation: M = metabolite
* Emerging drugs of abuse
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concentration. The hair sample (first 3-cm segment) 
was first decontaminated and subsequently 
subjected to simultaneous micro-pulverisation 
and extraction in solvent. The final filtrates were 
analysed by LC-MS/MS performed on an Agilent 
6430 triple-quadrupole mass spectrometer (Agilent 
Technologies, Singapore) coupled with Agilent 
1290 Infinity liquid chromatography system. The 
47 conventional and 47 emerging DOA identified 
for analysis are listed in Table 1. The analytical 
method had previously been validated according to 
international guidelines.12 
Statistical analysis
Statistical analysis was performed using Fisher’s 
exact test, with a P value of less than 0.05 considered 
statistically significant. Comparison of the drug 
detection rates was made between (i) different ethnic 
groups and (ii) samples collected in the rehabilitation 
and acute settings.  
Results
Subject demographics
In total, 972 individuals took part in the study (720 
males, 252 females). Their respective mean and 
median age was 35 and 33 years (range, 18-74 years). 
Of the 972 subjects, 815 were single-time donors 
and 157 donated repeated samples (between 2 and 6 
donations each). There were 1224 donation episodes 
(815 from single-time donors; 409 from repeated 
donors) and 2000 specimens collected in total, of 
which 964 were urine and 1036 were hair (Fig 1). 
Of the 1224 donation episodes, the subjects were 
recruited from: substance abuse clinics (n=822), 
drug rehabilitation and counselling centres (n=320), 
youth hangout centre (n=41), HKPIC toxicology 
clinic (n=28), and A&E departments (n=13). 
Emerging drugs of abuse
In the 2000 specimens analysed, five specimens were 
found to contain three emerging DOAs: PMMA, 
TFMPP, and methcathinone. A methamphetamine 
derivative, PMMA, was detected in three hair 
specimens (cases 1-3, Table 2). All three hair samples 
TABLE 2.  Emerging drugs of abuse detected in the study
Case No. Sex/age (years) Setting Drugs detected in hair Drugs detected in urine

























5 F/27 SAC (Hair not collected) Methcathinone
Amphetamine
Methamphetamine
HMMA (metabolite of amphetamine-like substances)
Cocaine metabolite 
Abbreviations:  A&E = accident and emergency department; HKPIC = Hong Kong Poison Information Centre; PMMA = paramethoxymethamphetamine; 
SAC = substance abuse clinic; TFMPP = 1-(3-Trifluoromethylphenyl)piperazine
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were also found to contain cocaine and ketamine. 
Nonetheless, PMMA was not detected in the 
subjects’ concurrent urine sample. 
 A piperazine derivative, TFMPP, was detected 
in one urine specimen (case 4, Table 2), together with 
cocaine and ketamine. Nonetheless TFMPP  was not 
detected in the parallel hair sample. 
 Methcathinone, also known as ephedrone, is 
a cathinone (beta-keto amphetamine) analogue. It 
was detected in combination with amphetamine, 
methamphetamine, and cocaine metabolite in one 
urine specimen (case 5, Table 2). No parallel hair 
specimen was available from this subject.
Conventional drugs of abuse
Analysis of the 964 urine samples revealed the 
presence of 19 types of conventional DOA (Fig 2a). 
Codeine was the most common, being detected in 
47% of the urine samples, followed by methadone 
(35%), heroin (22%), methamphetamine (21%), 
ketamine (20%), zopiclone (20%), amphetamine 
(17%), midazolam (17%), and dextromethorphan 
(14%). Cocaine and cannabis were detected in 6% 
and 3% of urine samples, respectively.
 In hair specimens (1036 in total), 14 types 
of conventional DOA were detected (Fig 2b). 
Codeine (36%) and methadone (35%) were the most 
FIG 2.  Conventional drugs of abuse detected in (a) urine and (b) hair samples as a percentage of the total number of samples 
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prevalent, followed by ketamine (34%), heroin (33%), 
methamphetamine (29%), dextromethorphan (28%), 
and zopiclone (26%). Cocaine and zolpidem were 
detected in 12% and 7% of the samples, respectively. 
Ethnic minority 
A subset of participants (n=130) were of South Asian 
ethnicity. These subjects donated 248 specimens in 
130 episodes. Their drug use pattern was significantly 
different to that of Chinese. Comparison of 
urinalysis results revealed that South Asians had a 
significantly higher proportion of opiate use such as 
heroin, methadone, and codeine (P<0.001) as well as 
dextromethorphan (P<0.05; Fig 3a). On the contrary, 
ketamine, zopiclone, and diazepam (P<0.001) as well 
as cocaine and amphetamine (P<0.05) were detected 
at significantly higher rates in Chinese compared 
with South Asians. Analysis of hair specimens 
showed a largely similar pattern of discrepancy 
between the two ethnicities (Fig 3b).
Collection site setting 
The urine samples in the current study were collected 
from different settings: 38 samples from acute setting 
(A&E departments and HKPIC toxicology clinic); 885 
samples from drug rehabilitation setting (substance 
abuse clinics, CCPSA and other rehabilitation 
centres); and 41 from a high-risk population (youth 
FIG 3.  Comparison of the drugs detected in (a) urine and (b) hair samples collected from Chinese (white bars) and South 
Asians (dark bars)
* P<0.001
































































































































































  #  Tang et al #
120 Hong Kong Med J  ⎥  Volume 21 Number 2  ⎥  April 2015  ⎥  www.hkmj.org
hangout). A comparison of drugs detected between 
the acute and rehabilitation settings revealed a 
significantly higher detection rate of ketamine 
and cocaine (P<0.001) in the former (Fig 4). Drugs 
such as codeine, methadone, heroin, zopiclone, and 
dextromethorphan were detected at higher rates in 
samples collected in a rehabilitation setting.
Discussion
Emerging DOA are constantly being monitored 
worldwide by agencies such as the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). In 2008, 13 emerging DOA were 
reported for the first time to EMCDDA; by 2012, 
73 new drugs had been reported within a year.1 
Recent years have also seen the emergence of such 
designer drugs in Hong Kong, some of which have 
caused severe morbidity and fatalities.4,5,7 The early 
identification of emerging drugs enables prompt 
counteractive measures in terms of their clinical 
and social management, and the surveillance of 
emerging drugs in the population is increasingly 
being adopted globally as a proactive approach to 
combat drug abuse.13-15 In view of this, the present 
study was conducted to validate a locally developed 
LC-MS/MS method to screen for emerging DOA 
in the local population whilst simultaneously 
monitoring routine DOA. The study was conducted 
over a 21-month period. Multiple clinical and social 
service units from across the city collaborated in 
the study for a wider geographical coverage and 
FIG 4.  Comparison of the drugs detected in urine samples collected under the rehabilitation (white bars) and acute (dark bars) 
settings
* P<0.001
† P<0.05 but ≥0.005
more representative results. In 2013, approximately 
10 069 drug abusers were reported in Hong Kong.16 
This study population (972 subjects) was estimated 
to represent 9.7% of the total potential subjects. 
Regarding the response or participation rate, due to 
practical concerns and limited manpower, it was not 
possible for every collaborating unit to document 
fully the number of subjects approached or the 
number who refused consent.
 The current results revealed the presence 
of three emerging drugs (PMMA, TFMPP, and 
methcathinone) in five specimens. This low 
prevalence is an expected finding due to the intrinsic 
nature of ‘emerging’ rather than ‘established’ 
drugs. Nevertheless, PMMA is a highly toxic 
methamphetamine derivative that has been sold on 
the drug market as MDMA (3,4-methylenedioxy-
methamphetamine) substitute.8 The drug has been 
reported to have caused up to 90 fatalities worldwide 
over the years, including eight fatalities in Taiwan.8,17 
In particular, PMMA-associated fatalities have also 
been reported recently in Hong Kong.6 
 On the other hand, TFMPP is a piperazine 
derivative with mild hallucinogenic effects and, 
when taken with another piperazine derivative 
benzylpiperazine (BZP), causes ecstasy-like 
effects.18 Piperazine derivatives are known to cause 
dissociative and sympathomimetic toxicity.19 The 
drug TFMPP was first reported in Hong Kong in 
20104 and has been identified as an emerging drug in 
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 Another emerging DOA detected in the 
study, methcathinone, gained popularity from the 
1970s to 1990s, and was recently reported as a ‘re-
emerging’ DOA in Sweden.14 It is an amphetamine-
like stimulant and is among a group of synthetic 
cathinone compounds, commonly known as “bath 
salts”, that have been associated with numerous 
fatalities worldwide.20 Other highly toxic cathinone 
derivatives include mephedrone and MDPV 
(methylenedioxypyrovalerone),9,10 both of which are 
also covered in the analytical method but were not 
detected in the current study.
 Of the conventional DOA, the opiates, 
methamphetamine, and ketamine were among 
the most frequently detected in this study. This is 
consistent with the data on reported drug abusers that 
was published by the local Central Registry of Drug 
Abuse.21 Since this manuscript focuses on screening 
for emerging DOA, detailed analysis of conventional 
drug use such as gender and age differences was not 
performed. However, an interesting finding was the 
observation that significantly higher proportions of 
South Asian drug abusers used opiates such as heroin, 
methadone, and codeine compared with Chinese; 
Chinese drug abusers were much more likely to 
use ketamine, cocaine, zopiclone, and diazepam. 
This highlights the ethnic differences in drug use 
and indicates that alternative approaches may be 
required for the clinical and social management of 
ethnic minorities in Hong Kong.
 It is of interest to note the particularly high 
percentage of ketamine and cocaine detected in 
urine samples collected at A&E departments and 
toxicology clinic compared with the other collection 
sites. This may indicate that these drugs carry a more 
acute and severe toxicity profile relative to the other 
drugs with a consequent need of hospitalisation. 
A previous study on drug driving in Hong Kong 
also reported ketamine as the most prevalent drug 
detected in driver casualties who presented to the 
A&E department.22 Comparison of hair analysis 
results was not made here, since the main focus 
was on the difference between acute and non-acute 
cases; hair specimens would be less helpful since this 
biological matrix does not reflect recent exposure to 
drugs (see below for further discussion). 
 The present study showed a broadly similar 
pattern in urine and hair matrices in terms 
of the conventional DOA detected. Cocaine, 
dextromethorphan, and zolpidem were detected at 
higher rates in hair compared with urine, and may 
indicate the relatively high deposition efficiency 
of these drugs in hair matrix. It should be noted, 
however, that the metabolites of zolpidem were not 
included in the current assay, and may decrease its 
sensitivity for detection in urine. Urine and hair 
specimens have different ‘detection windows’, that 
is, they reflect different time frames of drug intake. 
Detection in urine indicates recent intake (within 
hours/days); thus this matrix is useful for the 
management of acute toxicity and drug overdose. 
The detection window of hair is much longer 
(weeks/months), enabling this matrix to be used for 
monitoring long-term drug use or abstinence. 
 When interpreting the results of the current 
study, it should be noted that some drugs may 
have been taken for therapeutic reasons, for 
example codeine, methadone, phentermine, or the 
tranquilizers/benzodiazepines. It was not possible in 
this study to differentiate medical use from abuse. It 
should also be noted that some drugs may be present 
as metabolites of others, for example temazepam and 
oxazepam (both of which are diazepam metabolites) 
and the emerging drug mCPP (metabolite of the 
antidepressant trazodone). Morphine is also the 
metabolite of codeine and heroin; it was only 
reported here as a drug in the absence of either 
codeine or heroin in the same sample.
 Effective control of novel drugs depends on 
their early identification. A number of means to 
monitor emerging DOA have been proposed, such 
as conducting population surveys, analysing online 
test purchases, or wastewater analysis.3 Population 
surveys suffer the potential drawback of obtaining 
inaccurate data, since the actual identity of the drugs 
may differ from the claimed ingredients, for example, 
BZP being sold as ‘MDMA’ tablets.23 Analysing 
drug items purchased online is a costly approach 
due to the vast number of products available. 
Wastewater analysis may be used for monitoring 
conventional DOA, but the approach may not be 
easily adapted to the surveillance of emerging drugs 
due to the anticipated minute levels (ng/L range) 
in wastewater.24 All the above approaches require 
a considerable amount of financial and manpower 
resources. We propose the integration of emerging 
DOA surveillance into the routine drug monitoring 
of patients using the established analytical method. 
This surveillance approach is accurate, readily 
attainable, and is also achieved with minimal extra 
cost and effort since it is a convenient by-product of 
the routine drug monitoring of patients. Additionally, 
its applicability in A&E department patients allows 
the early identification of highly toxic novel drugs. 
 The proposed analytical method is LC-MS/
MS–based, and offers several advantages over 
traditional DOA testing by immunoassay methods. 
First, development of an immunoassay is a lengthy 
process (in terms of years) involving the generation 
of antibodies. Immunoassay analysis also depends 
solely on the availability of commercial kits. These 
features do not favour early detection of new 
compounds given the protean nature of emerging 
drugs. In contrast, LC-MS/MS–based methods 
are much more versatile, permitting in-house 
enhancement of the method to allow detection of 
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new compounds as soon as they enter the market. 
Second, although immunoassay methods require 
minimal capital investment, their running costs are 
high due to the generation of antibodies. On the 
other hand, LC-MS/MS methods require a high 
initial investment in analysers, but the running cost 
is lower in the long term as the reagents involved are 
relatively inexpensive. Lastly, unlike immunoassay 
methods that are only preliminary in nature 
and require further confirmatory testing, mass 
spectrometry analysis is already confirmatory with 
accurate and definitive results.
 In addition to laboratory analysis, the emerging 
DOA surveillance team requires the expertise of 
medical doctors to keep a close watch on emerging 
drugs on the market, especially those with high 
clinical toxicity. Based on this ‘toxico-intelligence’, 
scientists should then enhance the analytical method 
to include such emerging substances. Hence, the 
effective control of emerging drugs will require 
a team of trained medical doctors and scientists, 
as well as versatile technology that enables the 
continual expansion of analytical coverage. In view 
of the resource requirements, specialised toxicology 
centres may be better suited for the purpose.
 The present study has proven the concept that 
a locally developed analytical method is a valid tool 
to monitor emerging DOA whilst simultaneously 
performing regular DOA testing in patients. 
Implementation of the method in the routine drug 
monitoring of abusers will enable the continued and 
proactive surveillance of novel drugs in the population 
with minimal extra cost and effort. This surveillance 
gathers important information so that society can be 
prepared in terms of legislation, as well as social and 
clinical management of these potentially dangerous 
drugs. Further expansion of the analytical coverage 
will help keep abreast of the rapid and constant 
change in the designer drug scene.
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